Here at Endpoints we all agree: we love lists about the most valuable drugs in drugmakers pipeline. And that regularly brings us back to the analysts at EP Vantage.
Their phase III list is dominated by Roche, which is pulling off a string of blockbuster approvals. Regeneron and Sanofi, perhaps the best partners in biotech, have a clear shot with dupilumab. Lilly, which has begun to rack up badly needed successes in Phase III, is expected to score with abemaciclib (though CDK 4/6 will be competitive).
Not to take anything away from AstraZeneca and durvalumab, its PD-L1 therapy will be the fourth checkpoint drug to the market. The company is lagging leader Bristol-Myers Squibb, Merck, and more recently Roche. That’s cause for more trouble for durvalumab than some analysts are factoring in now.
For more, visit EP Vantage and see their data on most prized filed NDAs and phase III assets.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,400+ biopharma pros who read Endpoints News by email every day.Free Subscription